UK gene and cell therapy group Oxford BioMedica (LSE:OXB) saw its share price leap more than 19% to 862.40 pence today, after it announced a lucrative deal to commercialize its Parkinson’s disease candidate, which could be worth as much as $824 million.
The company has entered into an exclusive worldwide licensing agreement with Axovant Sciences (Nasdaq: AXON) to develop and commercialize OXB-102, a gene therapy developed by Oxford BioMedica for Parkinson’s disease utilizing the LentiVector platform.
The news had a dramatic impact on Axovant, whose shares were down nearly 70% so far this year, but skyrocketed 160% to $4.55 by close of trading Wednesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze